Blockchain Registration Transaction Record

PolyPid Secures $26.7M, Advances FDA Approval for Breakthrough SSI Prevention

PolyPid Ltd. raises $26.7M post-SHIELD II trial success, advancing D-PLEX₁₀₀ towards FDA approval for surgical infection prevention, marking a leap in healthcare innovation.

This news is pivotal for healthcare systems, patients, and investors alike. For healthcare providers, D-PLEX₁₀₀ offers a potent tool to combat surgical site infections, which are not only costly but also life-threatening. Patients stand to benefit from significantly reduced infection rates, enhancing recovery outcomes. For investors, PolyPid represents a rare opportunity to invest in a company with a transformative product on the verge of FDA approval, backed by strong clinical results and a clear path to commercialization, all at a valuation that appears undervalued compared to peers.